Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Hepatocellular Carcinoma | Research article

Paracrine effects of CCN3 from non-cancerous hepatic cells increase signaling and progression of hepatocellular carcinoma

Authors: Weimin Li, Xia Liao, Pengbo Ning, Yu Cao, Mei Zhang, Yang Bu, Jun Lv, Qingan Jia

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

The liver microenvironment plays a key role in the progression and metastasis of hepatocellular carcinoma (HCC). Gene expression profiling of non-cancerous hepatic tissues obtained from patients with metastatic HCC exhibit a unique immune response signature, including upregulation of CCN3. However, the role of CCN3 secreted from non-cancerous hepatic tissues in the progression of HCC remains unclear.

Methods

Using tissue microarrays, we examined CCN3 in non-cancerous hepatic tissues of patients with HCC and correlated expression with clinical and pathological features. In addition, CCN3 localization and mechanisms of HCC progression were investigated in tissues and cell lines. Finally, correlations between CCN3 and cirrhosis were explored in patients.

Results

CCN3 was primarily localized to hepatic cells of non-cancerous hepatic tissues and was associated with vascular invasion and poor prognosis in patients with HCC. CCN3 expression in non-cancerous hepatic tissues also correlated with the degree of liver fibrosis. Compared with conditioned media from wild-type LO2 cells, conditioned media from hepatic cell line LO2 activated by LX2 (aLO2-CM) induced CCN3 expression and HCC cell proliferation and metastasis. Further, aLO2-CM activated MAPK signaling and epithelial-mesenchymal transition in HCC cells. Finally, CCN3 was inversely related to cirrhosis in the prognosis of HCC and negatively regulated hepatic stellate cells (HSCs) in vitro with downregulation of α-SMA, TGF-β, and collagens.

Conclusions

CCN3 was secreted from hepatic cells activated by HSCs and increased MAPK signaling, EMT, proliferation and metastasis of HCC cells. CCN3 was also inversely related to cirrhosis, regulating HSCs through a negative feedback loop.
Literature
1.
go back to reference Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef
2.
go back to reference Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–55.CrossRef Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–55.CrossRef
3.
go back to reference Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.CrossRef Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.CrossRef
4.
go back to reference Lv Z, Cai X, Weng X, Xiao H, Du C, Cheng J, Zhou L, Xie H, Sun K, Wu J, et al. Tumor–stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation. Surgery. 2015;158(1):142–50.CrossRef Lv Z, Cai X, Weng X, Xiao H, Du C, Cheng J, Zhou L, Xie H, Sun K, Wu J, et al. Tumor–stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation. Surgery. 2015;158(1):142–50.CrossRef
5.
go back to reference Budhu A, Forgues M, Ye Q, Jia H, He P, Zanetti K, Kammula U, Chen Y, Qin L, Tang Z, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10(2):99–111.CrossRef Budhu A, Forgues M, Ye Q, Jia H, He P, Zanetti K, Kammula U, Chen Y, Qin L, Tang Z, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10(2):99–111.CrossRef
6.
go back to reference Jia Q, Dong Q, Qin L. CCN: core regulatory proteins in the microenvironment that affect the metastasis of hepatocellular carcinoma? Oncotarget. 2016;7(2):1203–14.CrossRef Jia Q, Dong Q, Qin L. CCN: core regulatory proteins in the microenvironment that affect the metastasis of hepatocellular carcinoma? Oncotarget. 2016;7(2):1203–14.CrossRef
7.
go back to reference Jia Q, Xue T, Zhang Q, Cheng W, Zhang C, Ma J, Bu Y, Yu S, Liu Q. CCN3 is a therapeutic target relating enhanced stemness and coagulation in hepatocellular carcinoma. Sci Rep. 2017;7(1):13846.CrossRef Jia Q, Xue T, Zhang Q, Cheng W, Zhang C, Ma J, Bu Y, Yu S, Liu Q. CCN3 is a therapeutic target relating enhanced stemness and coagulation in hepatocellular carcinoma. Sci Rep. 2017;7(1):13846.CrossRef
8.
go back to reference Jia Q, Ren Z, Bu Y, Wang Z, Zhang Q, Liang L, Jiang X, Zhang Q, Tang Z. Herbal Compound "Songyou Yin" Renders Hepatocellular Carcinoma Sensitive to Oxaliplatin through Inhibition of Stemness. Evid Based Complement Alternat Med. 2012;2012:908601.PubMedPubMedCentral Jia Q, Ren Z, Bu Y, Wang Z, Zhang Q, Liang L, Jiang X, Zhang Q, Tang Z. Herbal Compound "Songyou Yin" Renders Hepatocellular Carcinoma Sensitive to Oxaliplatin through Inhibition of Stemness. Evid Based Complement Alternat Med. 2012;2012:908601.PubMedPubMedCentral
9.
go back to reference Jia QA, Wang ZM, Ren ZG, Bu Y, Xie XY, Wang YH, Zhang L, Zhang QB, Xue TC, Deng LF, et al. Herbal compound "Songyou yin" attenuates hepatoma cell invasiveness and metastasis through downregulation of cytokines secreted by activated hepatic stellate cells. BMC Complement Altern Med. 2013;13:89.CrossRef Jia QA, Wang ZM, Ren ZG, Bu Y, Xie XY, Wang YH, Zhang L, Zhang QB, Xue TC, Deng LF, et al. Herbal compound "Songyou yin" attenuates hepatoma cell invasiveness and metastasis through downregulation of cytokines secreted by activated hepatic stellate cells. BMC Complement Altern Med. 2013;13:89.CrossRef
10.
go back to reference Coulouarn C, Clement B. Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma. J Hepatol. 2014;60(6):1306–9.CrossRef Coulouarn C, Clement B. Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma. J Hepatol. 2014;60(6):1306–9.CrossRef
11.
go back to reference Eiró N, Vizoso F. Importance of tumor/stroma interactions in prognosis of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2014;3(2):98–101.PubMedPubMedCentral Eiró N, Vizoso F. Importance of tumor/stroma interactions in prognosis of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2014;3(2):98–101.PubMedPubMedCentral
12.
go back to reference Hernandez–Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144(3):512–27.CrossRef Hernandez–Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144(3):512–27.CrossRef
13.
go back to reference Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5, Supplement 1):S35–50.CrossRef Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5, Supplement 1):S35–50.CrossRef
14.
go back to reference Carloni V, Luong T, Rombouts K. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver Int. 2014;34(6):834–43.CrossRef Carloni V, Luong T, Rombouts K. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver Int. 2014;34(6):834–43.CrossRef
15.
go back to reference Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of Hepatocarcinogenesis. Hepatology. 2012;56(2):769–75.CrossRef Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of Hepatocarcinogenesis. Hepatology. 2012;56(2):769–75.CrossRef
16.
go back to reference Coulouarn C, Clément B. Stellate cells and the development of liver cancer: Therapeutic potential of targeting the stroma. 2014;60. Coulouarn C, Clément B. Stellate cells and the development of liver cancer: Therapeutic potential of targeting the stroma. 2014;60.
17.
go back to reference Räsänen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res. 2010;316(17):2713–22.CrossRef Räsänen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res. 2010;316(17):2713–22.CrossRef
18.
go back to reference Bu Y, Jia Q, Ren Z, Zhang J, Jiang X, Liang L, Xue T, Zhang Q, Wang Y, Zhang L, et al. Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1. PLoS One. 2014;9(3):e89686.CrossRef Bu Y, Jia Q, Ren Z, Zhang J, Jiang X, Liang L, Xue T, Zhang Q, Wang Y, Zhang L, et al. Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1. PLoS One. 2014;9(3):e89686.CrossRef
19.
go back to reference Jia Q, Wang Z, Ren Z, Bu Y, Xie X, Wang Y, Zhang L, Zhang Q, Xue T, Deng L, et al. Herbal compound "Songyou yin" attenuates hepatoma cell invasiveness and metastasis through downregulation of cytokines secreted by activated hepatic stellate cells. BMC Complement Altern Med. 2013;13:89.CrossRef Jia Q, Wang Z, Ren Z, Bu Y, Xie X, Wang Y, Zhang L, Zhang Q, Xue T, Deng L, et al. Herbal compound "Songyou yin" attenuates hepatoma cell invasiveness and metastasis through downregulation of cytokines secreted by activated hepatic stellate cells. BMC Complement Altern Med. 2013;13:89.CrossRef
20.
go back to reference Perbal B. CCN proteins: a centralized communication network. J Cell Commun Signal. 2013;7(3):169–77.CrossRef Perbal B. CCN proteins: a centralized communication network. J Cell Commun Signal. 2013;7(3):169–77.CrossRef
21.
go back to reference Vallacchi V, Daniotti M, Ratti F, Di Stasi D, Deho P, De Filippo A, Tragni G, Balsari A, Carbone A, Rivoltini L, et al. CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res. 2008;68(3):715–23.CrossRef Vallacchi V, Daniotti M, Ratti F, Di Stasi D, Deho P, De Filippo A, Tragni G, Balsari A, Carbone A, Rivoltini L, et al. CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res. 2008;68(3):715–23.CrossRef
22.
go back to reference Chen L, Brigstock DR. Analysis of pathological activities of CCN proteins in fibrotic diseases: Liver fibrosis. Methods Mol Biol. 2017;1489:445–63.CrossRef Chen L, Brigstock DR. Analysis of pathological activities of CCN proteins in fibrotic diseases: Liver fibrosis. Methods Mol Biol. 2017;1489:445–63.CrossRef
23.
go back to reference Leask A. Yin and Yang revisited: CCN3 as an anti-fibrotic therapeutic? J Cell Commun Signal. 2015;9(1):97–8.CrossRef Leask A. Yin and Yang revisited: CCN3 as an anti-fibrotic therapeutic? J Cell Commun Signal. 2015;9(1):97–8.CrossRef
Metadata
Title
Paracrine effects of CCN3 from non-cancerous hepatic cells increase signaling and progression of hepatocellular carcinoma
Authors
Weimin Li
Xia Liao
Pengbo Ning
Yu Cao
Mei Zhang
Yang Bu
Jun Lv
Qingan Jia
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5603-7

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine